RT Journal Article
SR Electronic
T1 Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21267519
DO 10.1101/2021.12.30.21267519
A1 Junker, Daniel
A1 Becker, Matthias
A1 Wagner, Teresa R.
A1 Kaiser, Philipp D.
A1 Maier, Sandra
A1 Grimm, Tanja M.
A1 Griesbaum, Johanna
A1 Marsall, Patrick
A1 Gruber, Jens
A1 Traenkle, Bjoern
A1 Heinzel, Constanze
A1 Pinilla, Yudi T.
A1 Held, Jana
A1 Fendel, Rolf
A1 Kreidenweiss, Andrea
A1 Nelde, Annika
A1 Maringer, Yacine
A1 Schroeder, Sarah
A1 Walz, Juliane S.
A1 Althaus, Karina
A1 Uzun, Gunalp
A1 Mikus, Marco
A1 Bakchoul, Tamam
A1 Schenke-Layland, Katja
A1 Bunk, Stefanie
A1 Haeberle, Helene
A1 Göpel, Siri
A1 Bitzer, Michael
A1 Renk, Hanna
A1 Remppis, Jonathan
A1 Engel, Corinna
A1 Franz, Axel R.
A1 Harries, Manuela
A1 Kessel, Barbora
A1 Strengert, Monika
A1 Krause, Gerard
A1 Zeck, Anne
A1 Rothbauer, Ulrich
A1 Dulovic, Alex
A1 Schneiderhan-Marra, Nicole
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21267519.abstract
AB The rapid emergence of the Omicron variant and its large number of mutations has led to its classification as a variant of concern (VOC) by the WHO(1). Initial studies on the neutralizing response towards this variant within convalescent and vaccinated individuals have identified substantial reductions(2-8). However many of these sample sets used in these studies were either small, uniform in nature, or were compared only to wild-type (WT) or, at most, a few other VOC. Here, we assessed IgG binding, (Angiotensin-Converting Enzyme 2) ACE2 binding inhibition, and antibody binding dynamics for the omicron variant compared to all other VOC and variants of interest (VOI)(9), in a large cohort of infected, vaccinated, and infected and then vaccinated individuals. While omicron was capable of binding to ACE2 efficiently, antibodies elicited by infection or immunization showed reduced IgG binding and ACE2 binding inhibition compared to WT and all VOC. Among vaccinated samples, antibody binding responses towards omicron were only improved following administration of a third dose. Overall, our results identify that omicron can still bind ACE2 while pre-existing antibodies can bind omicron. The extent of the mutations appear to inhibit the development of a neutralizing response, and as a result, omicron remains capable of evading immune control.Competing Interest StatementNSM was a speaker at previous Luminex user meetings. The NMI is involved in applied research projects as a fee for services with the Luminex Corporation. All other authors declare no competing interests.Funding StatementThis work was financially supported by the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68), the Initiative and Networking Fund of the Helmholtz Association of German Research Centres (grant number SO-96), the EU Horizon 2020 research and innovation program (grant agreement number 101003480 - CORESMA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed written consent was obtained from all study participants. Ethical approval and oversight for the samples used in this study was provided by the following ethics committees: the Ethics Committee of the University Hospital Tuebingen (293/2020BO2, 764/2020/BO2 (amended 6.12.21), B312/2020BO1 (amended 02.06.21), 556/2021BO1), the Ethics Committee of the University of Tuebingen (179/2020/BO2, 188/2020A) and the Ethics Committee of Hannover Medical School (9086_BO_S_2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.